Metabolic
14 drugs are in development for Obesity.
- Companies
- 10
- Clinical trials
- 302
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Obesity pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(2)
| Drug | Company |
|---|---|
| contrave | Orexigen Therapeutics, Inc. (OREX) |
| mysimba | Orexigen Therapeutics, Inc. (OREX) |
Phase 2(2)
Phase 1(5)
| Drug | Company |
|---|---|
| ACCG-2671 | Structure Therapeutics Inc. (GPCR) |
| BMF-650 | Biomea Fusion, Inc. (BMEA) |
| da-1726 | MetaVia Inc. (MTVA) |
| mbx 4291 | MBX Biosciences, Inc. (MBX) |
| rt-114 | Rani Therapeutics Holdings, Inc. (RANI) |
Preclinical(3)
| Drug | Company |
|---|---|
| accg-3535 | Structure Therapeutics Inc. (GPCR) |
| oral oxm | Entera Bio Ltd. (ENTX) |
| sln098 | Silence Therapeutics Plc (SLN) |
Phase 4(2)
About this indication
Obesity context
Metabolic·MeSH: Obesity (D009765)
Prevalence
42000.0 / 100K
Incidence
2000.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Obesity?
BioSniper tracks 14 drugs in development for Obesity across 10 companies.
How many clinical trials target Obesity?
There are 302 clinical trials targeting Obesity tracked by BioSniper.
What is the prevalence of Obesity?
The estimated prevalence of Obesity is approximately 42000.0 per 100,000 population.